Latest Biotech News

The FDA granted breakthrough therapy designation to Eli Lilly’s next-generation KRAS G12C inhibitor olomorasib for patients with advanced pancreatic cancer whose disease is KRAS G12C–mutant and...

The FDA approved Novartis’ radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor for men with PSMA-positive metastatic...

Novartis’ Pluvicto received FDA clearance in an earlier prostate cancer stage, in tandem with an androgen receptor pathway inhibitor, for patients with PSMA-positive metastatic hormone-sensitive...

Curium Pharma agreed to acquire Lantheus Holdings in a definitive deal valued at up to $8 billion, strengthening both firms’ theranostics and radiodiagnostics footprints. Curium will pay $114.50...

Supernus Pharmaceuticals and Indivior announced a tax-free, all-stock merger of equals, combining to create a CNS-focused company under the Supernus name. The companies said the deal is structured...

Sandoz agreed to resolve lingering U.S. antitrust claims over alleged generic drug price-fixing through a pair of settlement agreements. The settlements cover claims brought by 43 U.S. states and...

Inocras closed a $31 million Series B-3 financing round to expand its whole-genome sequencing offering and clinical footprint in the United States. The company, formerly Genome Insight and a...

Twist Bioscience reported fiscal Q3 2026 revenue growth of 23% year over year, reaching $118.4 million, driven by continued strength across DNA synthesis, protein solutions, and NGS applications....

Craig-Hallum upgraded CareDx to a Buy rating and raised its price target to $64 per share, citing growth drivers tied to reimbursement momentum and assay expansion. The analyst pointed to CareDx’s...

Capricor’s Deramiocel faced a major hurdle as an FDA Cellular, Tissue, and Gene Therapies Advisory Committee recommended against approval of the company’s resubmitted biologics license...

FDA has expanded the indication for Novartis’ radioligand therapy Pluvicto into an earlier stage of prostate cancer, approving it for PSMA-positive metastatic hormone-sensitive prostate cancer...

BioNTech has named Guido Oelkers, formerly CEO of Swedish biopharma Sobi, as its next CEO, continuing the company’s shift from COVID-era mRNA manufacturing toward an oncology-focused...

Novo Nordisk’s IL-6 inhibitor ziltivekimab has failed to meet its primary cardiovascular endpoint in the phase 3 ZEUS trial, dashing expectations that lowering inflammation would translate into...

Capricor’s Deramiocel has been rejected again by an FDA advisory committee, with members concluding that the evidence from the HOPE-3 phase 3 trial does not provide substantial effectiveness for...

Curium has agreed to buy radiopharma peer Lantheus in an $8 billion deal, expanding scale in radioligand and imaging-focused oncology while reshaping the competitive landscape for...

Sandoz has agreed to settle key components of long-running US antitrust litigation tied to alleged generic drug price-fixing, reaching agreements with multiple sets of claimants to substantially...

Dash Bio has raised a $30 million Series A led by Oak HC/FT to expand its pharma lab services platform, aiming to provide research and operational support to biotechnology and pharmaceutical...

Twist Bioscience reported fiscal Q3 2026 revenue growth of 23% year over year to $118.4 million, driven by double-digit increases across DNA synthesis and protein solutions and its NGS...

Supernus Pharmaceuticals and Indivior have signed an all-stock merger agreement to form a CNS-focused company, combining their marketed neurological and substance-use disorder portfolios. The...

Amgen disclosed that hackers stole company and patient information in a cloud data breach involving data hosted by third-party providers. Amgen said it detected unauthorized activity affecting...